Baicalin promotes antiviral IFNs production and alleviates type I IFN-induced neutrophil inflammation

J Nat Med. 2023 Sep;77(4):677-687. doi: 10.1007/s11418-023-01702-0. Epub 2023 Jul 25.

Abstract

Type I and III interferons (IFNs) both serve as pivotal components of the host antiviral innate immune system. Although they exert similar antiviral effects, type I IFNs can also activate neutrophil inflammation, a function not born by type III IFNs. Baicalin, the main bioactive component of Scutellariae radix, has been shown to exert therapeutic effects on viral diseases due to its anti-viral, anti-inflammatory and immunomulatory activities. There is uncertainty, however, on the association between the antiviral effects of baicalin and the modulation of anti-viral IFNs production and the immunological effects of type I IFNs. Here, a Poly (I:C)-stimulated A549 cell line was established to mimic a viral infection model. Our results demonstrated that baicalin could elevate the expression of type I and III IFNs and their receptors in Poly (I:C)-stimulated A549 cells. Moreover, the potential regulation effects of baicalin for type I IFN-induced neutrophil inflammation was further explored. Results showed that baicalin diminished the production of the pro-inflammatory cytokines (IL-1β, IL-6, IL-17 and TNF-α), ROS, and neutrophil extracellular traps and suppressed chemotaxis. Collectively, all these data indicated that baicalin had a dual role on IFNs production and effects: (1) Baicalin was able to elevate the expression of type I and III IFNs and their receptors, (2) and it alleviated type I IFN-mediated neutrophil inflammatory response. This meant that baicalin has the potential to act as an eximious immunomodulator, exerting antiviral effects and reducing inflammation.

Keywords: Anti-virus; Baicalin; Inflammation; Interferon; Neutrophils.

MeSH terms

  • Antiviral Agents* / pharmacology
  • Humans
  • Inflammation / drug therapy
  • Interferon Type I* / metabolism
  • Neutrophils / metabolism

Substances

  • Antiviral Agents
  • baicalin
  • Interferon Type I